-
New video launched: How does EMA support SMEs?
New video launched: How does EMA support SMEs?
-
New video launched: How does EMA support SMEs?
New video launched: How does EMA support SMEs?
EMA has prepared and published a short video in German, French, Italian, Spanish, Polish and Portuguese to explain how its dedicated office for small and medium enterprises helps SMEs across Europe.
-
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 10 – 13 February 2020
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 10 – 13 February 2020
-
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 10 – 13 February 2020
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 10 – 13 February 2020
PRAC recommends restrictions in use of cyproterone due to meningioma risk. Direct healthcare professional communications (DHPCs) to be regularly published on EMA website.
-
EMA to support development of vaccines and treatments for novel coronavirus disease (COVID-19)
EMA to support development of vaccines and treatments for novel coronavirus disease (COVID-19)
-
EMA to support development of vaccines and treatments for novel coronavirus disease (COVID-19)
EMA to support development of vaccines and treatments for novel coronavirus disease (COVID-19)
To contribute to the global response to the outbreak of the novel coronavirus infections, EMA is taking concrete actions to accelerate the development and availability of medicinal products for the treatment and prevention of the new coronavirus.
-
Public access to suspected side effect reports of veterinary medicines
Public access to suspected side effect reports of veterinary medicines
-
Public access to suspected side effect reports of veterinary medicines
Public access to suspected side effect reports of veterinary medicines
EMA is making suspected side effect reports of veterinary medicines authorised in the EU publicly accessible through www.adrreports.eu.
